ALFA Finder| Revenue growth | FY26 Standalone: 1.5% YoY; Q4FY26: 9.5% YoY. |
|---|---|
| Margins | FY26 Standalone EBITDA margin at 22.59% vs 24.08% FY25. |
| Order book | CDMO logged highest ever quarterly revenue at INR 155 Cr. |
| Management confidence | Targeting 15-18% CAGR over next 3-4 years. |
Growth
FY26 standalone revenue grew 1.5% YoY; Q4FY26 revenue surged 36.3% QoQ. CDMO sales grew significantly to INR 276 Cr.
Outlook
Targeting 15-18% Revenue/EBITDA CAGR over 3-4 years. FY27 CAPEX outlook INR 400 Cr; Atali Phase 1 fully operational Jun'26.
Risks
Geopolitical tensions causing input and logistics price hikes; difficult cost pass-through in API/Intermediates segments.
Earnings Call filed with NSE, NSE: AARTIPHARM. Summary written with AI assistance from the document.
Aarti Pharmalabs Ltd: key numbers
- Share price
- ₹923.50
- Market cap
- ₹8,374 Cr
- Revenue (annual)
- ₹1,819 Cr
- Net profit (annual)
- ₹174.7 Cr
- P/E (TTM)
- 32.6×Sector 43.8×
- Promoter holding
- 39.66%-3.20% QoQ
- FII holding
- 8.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Pharmalabs Ltd
All →Aarti Pharmalabs Earnings Call Transcript: Key Takeaways
Aarti Pharmalabs delivered record quarterly revenue driven by strong CDMO growth, though aggressive capex is temporarily elevating debt and working capital.
- Call
- Guides 45% growth
Aarti Pharmalabs Investor Presentation: Key Takeaways
Q2 FY27 standalone revenue INR 6,126Mn (+46.8% YoY), EBITDA INR 1,358Mn (22.2% margin), PAT INR 658Mn (+180% YoY). H1 revenue +44.7%. Xanthine capacity expansion and Atali capex drive growth.
Aarti Pharmalabs Management Change
Aarti Pharmalabs accepted CFO Piyush Lakhani's resignation, effective 30 October 2026, and appointed Vibha Thakker as CFO from 31 October 2026. The filing records a senior management change with no monetary amount.
Aarti Pharmalabs Q2 FY27 Results: Net Profit ₹71.5 Cr, Up 248.8% YoY
Aarti Pharmalabs Ltd reported revenue from operations of ₹610.5 Cr (+45.9% YoY) and net profit of ₹71.5 Cr (+248.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹71.5 Cr · +248.8% YoY
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.